Charity Lowdermilk
Family · Arkadelphia, ARNPI 1902297559
Payments from drug & device makers
Across 102 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$297
- AbbVie$288
- Novo Nordisk$184
- Lilly USA, LLC$104
- Amgen$80
- Exact Sciences$78
- plus $383 from 14 others
What the payments were for
- Food & beverage$1,38398%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 17 | $297 |
| AbbVie(2 entities) | 31 | $288 |
| Novo Nordisk | 12 | $184 |
| Lilly USA, LLC | 6 | $104 |
| Amgen | 6 | $80 |
| Exact Sciences | 4 | $78 |
| Nestle Healthcare Nutrition Inc. | 5 | $69 |
| GSK | 4 | $64 |
| Novartis | 3 | $49 |
| Boehringer Ingelheim | 3 | $40 |
| Merck | 2 | $25 |
| AstraZeneca | 1 | $24 |
| Bausch Health US, LLC | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$1,413 in reported general payments places this provider in the 75th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $75,280 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $51,618 |
| EliquisApixaban | 18 | $25,149 |
| MounjaroTirzepatide | 21 | $22,856 |
| TrulicityDulaglutide | 21 | $22,737 |
| JanuviaSitagliptin Phosphate | 13 | $17,087 |
| LinzessLinaclotide | 13 | $12,884 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,220 |
| JardianceEmpagliflozin | 11 | $7,701 |
| Arnuity ElliptaFluticasone Furoate | 12 | $6,569 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $3,814 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $3,578 |
| Potassium Chloride | 169 | $2,778 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,679 |
| Gabapentin | 175 | $2,457 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $184 | $75,28061 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $64 | $58,18775 claims |
| Lilly USA, LLCMounjaro, Trulicity | $104 | $45,59342 claims |
| MerckJanuvia | $25 | $17,08713 claims |
| AbbVieLinzess | $288 | $12,88413 claims |
| AstraZenecaBreztri Aerosphere | $24 | $9,22011 claims |
| Boehringer IngelheimJardiance | $40 | $7,70111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,103 family providers in Arkansas.
Other family in Arkadelphia
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.